APO Research
Talk to an analyst

APO RESEARCH · REPORT

Single-target Anti-VEGF Drugs

Compare research editions
View pricing & licenses

Selected research

Industry Research

Single-target Anti-VEGF Drugs Industry Research Report 2026

27 December 2025122 pages

Choose your research edition.

Industry ResearchSingle-target Anti-VEGF Drugs Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Single-target Anti-VEGF Drugs Industry Growth and Trends Forecast to 203293 pages · $3,450 USDMarket StructureGlobal Single-target Anti-VEGF Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Single-target Anti-VEGF Drugs Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Single-target Anti-VEGF Drugs Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Single-target Anti-VEGF Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Single-target Anti-VEGF Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Single-target Anti-VEGF Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Single-target Anti-VEGF Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Single-target Anti-VEGF Drugs include Roche, Chengdu Kanghong Pharmaceutical, Samsung Bioepis, Regeneron Pharmaceuticals, Novartis, Coherus BioSciences and Biocon Biologics, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Single-target Anti-VEGF Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Single-target Anti-VEGF Drugs Market by Company

Roche

Chengdu Kanghong Pharmaceutical

Samsung Bioepis

Regeneron Pharmaceuticals

Novartis

Coherus BioSciences

Biocon Biologics

Single-target Anti-VEGF Drugs Segment by Type

Ranibizumab

Conbercept

Faricimab

Brolucizumab

Aflibercept

Other

Single-target Anti-VEGF Drugs Segment by Application

Diabetic Retinopathy

Age-related Macular Degeneration

Other

Single-target Anti-VEGF Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Single-target Anti-VEGF Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Single-target Anti-VEGF Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Single-target Anti-VEGF Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Single-target Anti-VEGF Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Single-target Anti-VEGF Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Single-target Anti-VEGF Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Single-target Anti-VEGF Drugs Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Single-target Anti-VEGF Drugs Sales (K Units) of Manufacturers (2021-2026) Table 7. Global Single-target Anti-VEGF Drugs Sales Market Share by Manufacturers (2021-2026) Table 8. Global Single-target Anti-VEGF Drugs Revenue of Manufacturers (2021-2026) Table 9. Global Single-target Anti-VEGF Drugs Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Single-target Anti-VEGF Drugs Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Single-target Anti-VEGF Drugs Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Single-target Anti-VEGF Drugs, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Single-target Anti-VEGF Drugs, Product Type & Application Table 14. Global Single-target Anti-VEGF Drugs Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Single-target Anti-VEGF Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Roche Company Information Table 19. Roche Business Overview Table 20. Roche Single-target Anti-VEGF Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. Roche Single-target Anti-VEGF Drugs Product Portfolio Table 22. Roche Recent Developments Table 23. Chengdu Kanghong Pharmaceutical Company Information Table 24. Chengdu Kanghong Pharmaceutical Business Overview Table 25. Chengdu Kanghong Pharmaceutical Single-target Anti-VEGF Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. Chengdu Kanghong Pharmaceutical Single-target Anti-VEGF Drugs Product Portfolio Table 27. Chengdu Kanghong Pharmaceutical Recent Developments Table 28. Samsung Bioepis Company Information Table 29. Samsung Bioepis Business Overview Table 30. Samsung Bioepis Single-target Anti-VEGF Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Samsung Bioepis Single-target Anti-VEGF Drugs Product Portfolio Table 32. Samsung Bioepis Recent Developments Table 33. Regeneron Pharmaceuticals Company Information Table 34. Regeneron Pharmaceuticals Business Overview Table 35. Regeneron Pharmaceuticals Single-target Anti-VEGF Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. Regeneron Pharmaceuticals Single-target Anti-VEGF Drugs Product Portfolio Table 37. Regeneron Pharmaceuticals Recent Developments Table 38. Novartis Company Information Table 39. Novartis Business Overview Table 40. Novartis Single-target Anti-VEGF Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. Novartis Single-target Anti-VEGF Drugs Product Portfolio Table 42. Novartis Recent Developments Table 43. Coherus BioSciences Company Information Table 44. Coherus BioSciences Business Overview Table 45. Coherus BioSciences Single-target Anti-VEGF Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Coherus BioSciences Single-target Anti-VEGF Drugs Product Portfolio Table 47. Coherus BioSciences Recent Developments Table 48. Biocon Biologics Company Information Table 49. Biocon Biologics Business Overview Table 50. Biocon Biologics Single-target Anti-VEGF Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Biocon Biologics Single-target Anti-VEGF Drugs Product Portfolio Table 52. Biocon Biologics Recent Developments Table 53. Global Single-target Anti-VEGF Drugs Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 54. Global Single-target Anti-VEGF Drugs Sales by Region (2021-2026) & (K Units) Table 55. Global Single-target Anti-VEGF Drugs Sales Market Share by Region (2021-2026) Table 56. Global Single-target Anti-VEGF Drugs Sales by Region (2027-2032) & (K Units) Table 57. Global Single-target Anti-VEGF Drugs Sales Market Share by Region (2027-2032) Table 58. Global Single-target Anti-VEGF Drugs Revenue by Region (2021-2026) & (US$ Million) Table 59. Global Single-target Anti-VEGF Drugs Revenue Market Share by Region (2021-2026) Table 60. Global Single-target Anti-VEGF Drugs Revenue by Region (2027-2032) & (US$ Million) Table 61. Global Single-target Anti-VEGF Drugs Revenue Market Share by Region (2027-2032) Table 62. North America Single-target Anti-VEGF Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 63. North America Single-target Anti-VEGF Drugs Sales by Country (2021-2026) & (K Units) Table 64. North America Single-target Anti-VEGF Drugs Sales by Country (2027-2032) & (K Units) Table 65. North America Single-target Anti-VEGF Drugs Revenue by Country (2021-2026) & (US$ Million) Table 66. North America Single-target Anti-VEGF Drugs Revenue by Country (2027-2032) & (US$ Million) Table 67. Europe Single-target Anti-VEGF Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 68. Europe Single-target Anti-VEGF Drugs Sales by Country (2021-2026) & (K Units) Table 69. Europe Single-target Anti-VEGF Drugs Sales by Country (2027-2032) & (K Units) Table 70. Europe Single-target Anti-VEGF Drugs Revenue by Country (2021-2026) & (US$ Million) Table 71. Europe Single-target Anti-VEGF Drugs Revenue by Country (2027-2032) & (US$ Million) Table 72. Asia Pacific Single-target Anti-VEGF Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 73. Asia Pacific Single-target Anti-VEGF Drugs Sales by Country (2021-2026) & (K Units) Table 74. Asia Pacific Single-target Anti-VEGF Drugs Sales by Country (2027-2032) & (K Units) Table 75. Asia Pacific Single-target Anti-VEGF Drugs Revenue by Country (2021-2026) & (US$ Million) Table 76. Asia Pacific Single-target Anti-VEGF Drugs Revenue by Country (2027-2032) & (US$ Million) Table 77. South America Single-target Anti-VEGF Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 78. South America Single-target Anti-VEGF Drugs Sales by Country (2021-2026) & (K Units) Table 79. South America Single-target Anti-VEGF Drugs Sales by Country (2027-2032) & (K Units) Table 80. South America Single-target Anti-VEGF Drugs Revenue by Country (2021-2026) & (US$ Million) Table 81. South America Single-target Anti-VEGF Drugs Revenue by Country (2027-2032) & (US$ Million) Table 82. Middle East and Africa Single-target Anti-VEGF Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 83. Middle East and Africa Single-target Anti-VEGF Drugs Sales by Country (2021-2026) & (K Units) Table 84. Middle East and Africa Single-target Anti-VEGF Drugs Sales by Country (2027-2032) & (K Units) Table 85. Middle East and Africa Single-target Anti-VEGF Drugs Revenue by Country (2021-2026) & (US$ Million) Table 86. Middle East and Africa Single-target Anti-VEGF Drugs Revenue by Country (2027-2032) & (US$ Million) Table 87. Global Single-target Anti-VEGF Drugs Sales by Type (2021-2026) & (K Units) Table 88. Global Single-target Anti-VEGF Drugs Sales by Type (2027-2032) & (K Units) Table 89. Global Single-target Anti-VEGF Drugs Sales Market Share by Type (2021-2026) Table 90. Global Single-target Anti-VEGF Drugs Sales Market Share by Type (2027-2032) Table 91. Global Single-target Anti-VEGF Drugs Revenue by Type (2021-2026) & (US$ Million) Table 92. Global Single-target Anti-VEGF Drugs Revenue by Type (2027-2032) & (US$ Million) Table 93. Global Single-target Anti-VEGF Drugs Revenue Market Share by Type (2021-2026) Table 94. Global Single-target Anti-VEGF Drugs Revenue Market Share by Type (2027-2032) Table 95. Global Single-target Anti-VEGF Drugs Price by Type (2021-2026) & (US$/Unit) Table 96. Global Single-target Anti-VEGF Drugs Price by Type (2027-2032) & (US$/Unit) Table 97. Global Single-target Anti-VEGF Drugs Sales by Application (2021-2026) & (K Units) Table 98. Global Single-target Anti-VEGF Drugs Sales by Application (2027-2032) & (K Units) Table 99. Global Single-target Anti-VEGF Drugs Sales Market Share by Application (2021-2026) Table 100. Global Single-target Anti-VEGF Drugs Sales Market Share by Application (2027-2032) Table 101. Global Single-target Anti-VEGF Drugs Revenue by Application (2021-2026) & (US$ Million) Table 102. Global Single-target Anti-VEGF Drugs Revenue by Application (2027-2032) & (US$ Million) Table 103. Global Single-target Anti-VEGF Drugs Revenue Market Share by Application (2021-2026) Table 104. Global Single-target Anti-VEGF Drugs Revenue Market Share by Application (2027-2032) Table 105. Global Single-target Anti-VEGF Drugs Price by Application (2021-2026) & (US$/Unit) Table 106. Global Single-target Anti-VEGF Drugs Price by Application (2027-2032) & (US$/Unit) Table 107. Key Raw Materials Table 108. Raw Materials Key Suppliers Table 109. Single-target Anti-VEGF Drugs Distributors List Table 110. Single-target Anti-VEGF Drugs Customers List Table 111. Single-target Anti-VEGF Drugs Industry Trends Table 112. Single-target Anti-VEGF Drugs Industry Drivers Table 113. Single-target Anti-VEGF Drugs Industry Restraints Table 114. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Single-target Anti-VEGF Drugs Product Image Figure 5. Global Single-target Anti-VEGF Drugs Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Single-target Anti-VEGF Drugs Market Size (2021-2032) & (US$ Million) Figure 7. Global Single-target Anti-VEGF Drugs Sales (2021-2032) & (K Units) Figure 8. Global Single-target Anti-VEGF Drugs Average Price (US$/Unit) & (2021-2032) Figure 9. Ranibizumab Product Image Figure 10. Conbercept Product Image Figure 11. Faricimab Product Image Figure 12. Brolucizumab Product Image Figure 13. Aflibercept Product Image Figure 14. Other Product Image Figure 15. Diabetic Retinopathy Product Image Figure 16. Age-related Macular Degeneration Product Image Figure 17. Other Product Image Figure 18. Global Single-target Anti-VEGF Drugs Revenue Share by Manufacturers in 2025 Figure 19. Global Manufacturers of Single-target Anti-VEGF Drugs, Manufacturing Sites & Headquarters Figure 20. Global Top 5 and 10 Single-target Anti-VEGF Drugs Players Market Share by Revenue in 2025 Figure 21. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 22. Global Single-target Anti-VEGF Drugs Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 23. Global Single-target Anti-VEGF Drugs Sales by Region in 2025 Figure 24. Global Single-target Anti-VEGF Drugs Revenue by Region in 2025 Figure 25. North America Single-target Anti-VEGF Drugs Market Size by Country in 2025 Figure 26. North America Single-target Anti-VEGF Drugs Sales Market Share by Country (2021-2032) Figure 27. North America Single-target Anti-VEGF Drugs Revenue Market Share by Country (2021-2032) Figure 28. United States Single-target Anti-VEGF Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 29. Canada Single-target Anti-VEGF Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 30. Mexico Single-target Anti-VEGF Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. Europe Single-target Anti-VEGF Drugs Market Size by Country in 2025 Figure 32. Europe Single-target Anti-VEGF Drugs Sales Market Share by Country (2021-2032) Figure 33. Europe Single-target Anti-VEGF Drugs Revenue Market Share by Country (2021-2032) Figure 34. Germany Single-target Anti-VEGF Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. France Single-target Anti-VEGF Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. U.K. Single-target Anti-VEGF Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Italy Single-target Anti-VEGF Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Russia Single-target Anti-VEGF Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Spain Single-target Anti-VEGF Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Netherlands Single-target Anti-VEGF Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Switzerland Single-target Anti-VEGF Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Sweden Single-target Anti-VEGF Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. Poland Single-target Anti-VEGF Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Asia Pacific Single-target Anti-VEGF Drugs Market Size by Country in 2025 Figure 45. Asia Pacific Single-target Anti-VEGF Drugs Sales Market Share by Country (2021-2032) Figure 46. Asia Pacific Single-target Anti-VEGF Drugs Revenue Market Share by Country (2021-2032) Figure 47. China Single-target Anti-VEGF Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Japan Single-target Anti-VEGF Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. South Korea Single-target Anti-VEGF Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. India Single-target Anti-VEGF Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Australia Single-target Anti-VEGF Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Taiwan Single-target Anti-VEGF Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. Southeast Asia Single-target Anti-VEGF Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. Southeast Asia Single-target Anti-VEGF Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. South America Single-target Anti-VEGF Drugs Market Size by Country in 2025 Figure 56. South America Single-target Anti-VEGF Drugs Sales Market Share by Country (2021-2032) Figure 57. South America Single-target Anti-VEGF Drugs Revenue Market Share by Country (2021-2032) Figure 58. Brazil Single-target Anti-VEGF Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 59. Argentina Single-target Anti-VEGF Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 60. Chile Single-target Anti-VEGF Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. Middle East and Africa Single-target Anti-VEGF Drugs Market Size by Country in 2025 Figure 62. Middle East and Africa Single-target Anti-VEGF Drugs Sales Market Share by Country (2021-2032) Figure 63. Middle East and Africa Single-target Anti-VEGF Drugs Revenue Market Share by Country (2021-2032) Figure 64. Egypt Single-target Anti-VEGF Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. South Africa Single-target Anti-VEGF Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. Israel Single-target Anti-VEGF Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 67. Türkiye Single-target Anti-VEGF Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 68. GCC Countries Single-target Anti-VEGF Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 69. Global Single-target Anti-VEGF Drugs Sales Market Share by Type (2021-2032) Figure 70. Global Single-target Anti-VEGF Drugs Revenue Market Share by Type (2021-2032) Figure 71. Global Single-target Anti-VEGF Drugs Price (US$/Unit) by Type (2021-2032) Figure 72. Global Single-target Anti-VEGF Drugs Sales Market Share by Application (2021-2032) Figure 73. Global Single-target Anti-VEGF Drugs Revenue Market Share by Application (2021-2032) Figure 74. Global Single-target Anti-VEGF Drugs Price (US$/Unit) by Application (2021-2032) Figure 75. Single-target Anti-VEGF Drugs Value Chain Figure 76. Single-target Anti-VEGF Drugs Production Mode & Process Figure 77. Direct Comparison with Distribution Share Figure 78. Distributors Profiles Figure 79. Single-target Anti-VEGF Drugs Industry Opportunities and Challenges

Scope & coverage.

Types
  • Ranibizumab
  • Conbercept
  • Faricimab
  • Brolucizumab
  • Aflibercept
  • Other
Applications
  • Diabetic Retinopathy
  • Age-related Macular Degeneration
  • Other
Companies covered
  • Roche
  • Chengdu Kanghong Pharmaceutical
  • Samsung Bioepis
  • Regeneron Pharmaceuticals
  • Novartis
  • Coherus BioSciences
  • Biocon Biologics

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Single-target Anti-VEGF Drugs Market Size (2021-2032)
  4. 2.2.2 Global Single-target Anti-VEGF Drugs Sales (2021-2032)
  5. 2.2.3 Global Single-target Anti-VEGF Drugs Market Average Price (2021-2032)
  6. 2.3 Single-target Anti-VEGF Drugs by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Ranibizumab
  9. 2.3.3 Conbercept
  10. 2.3.4 Faricimab
  11. 2.3.5 Brolucizumab
  12. 2.3.6 Aflibercept
  13. 2.3.7 Other
  14. 2.4 Single-target Anti-VEGF Drugs by Application
  15. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  16. 2.4.2 Diabetic Retinopathy
  17. 2.4.3 Age-related Macular Degeneration
  18. 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Single-target Anti-VEGF Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Single-target Anti-VEGF Drugs Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global Single-target Anti-VEGF Drugs Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Single-target Anti-VEGF Drugs Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Single-target Anti-VEGF Drugs Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Single-target Anti-VEGF Drugs, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Single-target Anti-VEGF Drugs, Product Type & Application
  8. 3.8 Global Manufacturers of Single-target Anti-VEGF Drugs, Established Date
  9. 3.9 Global Single-target Anti-VEGF Drugs Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Roche
  2. 4.1.1 Roche Company Information
  3. 4.1.2 Roche Business Overview
  4. 4.1.3 Roche Single-target Anti-VEGF Drugs Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Roche Single-target Anti-VEGF Drugs Product Portfolio
  6. 4.1.5 Roche Recent Developments
  7. 4.2 Chengdu Kanghong Pharmaceutical
  8. 4.2.1 Chengdu Kanghong Pharmaceutical Company Information
  9. 4.2.2 Chengdu Kanghong Pharmaceutical Business Overview
  10. 4.2.3 Chengdu Kanghong Pharmaceutical Single-target Anti-VEGF Drugs Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Chengdu Kanghong Pharmaceutical Single-target Anti-VEGF Drugs Product Portfolio
  12. 4.2.5 Chengdu Kanghong Pharmaceutical Recent Developments
  13. 4.3 Samsung Bioepis
  14. 4.3.1 Samsung Bioepis Company Information
  15. 4.3.2 Samsung Bioepis Business Overview
  16. 4.3.3 Samsung Bioepis Single-target Anti-VEGF Drugs Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Samsung Bioepis Single-target Anti-VEGF Drugs Product Portfolio
  18. 4.3.5 Samsung Bioepis Recent Developments
  19. 4.4 Regeneron Pharmaceuticals
  20. 4.4.1 Regeneron Pharmaceuticals Company Information
  21. 4.4.2 Regeneron Pharmaceuticals Business Overview
  22. 4.4.3 Regeneron Pharmaceuticals Single-target Anti-VEGF Drugs Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Regeneron Pharmaceuticals Single-target Anti-VEGF Drugs Product Portfolio
  24. 4.4.5 Regeneron Pharmaceuticals Recent Developments
  25. 4.5 Novartis
  26. 4.5.1 Novartis Company Information
  27. 4.5.2 Novartis Business Overview
  28. 4.5.3 Novartis Single-target Anti-VEGF Drugs Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Novartis Single-target Anti-VEGF Drugs Product Portfolio
  30. 4.5.5 Novartis Recent Developments
  31. 4.6 Coherus BioSciences
  32. 4.6.1 Coherus BioSciences Company Information
  33. 4.6.2 Coherus BioSciences Business Overview
  34. 4.6.3 Coherus BioSciences Single-target Anti-VEGF Drugs Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Coherus BioSciences Single-target Anti-VEGF Drugs Product Portfolio
  36. 4.6.5 Coherus BioSciences Recent Developments
  37. 4.7 Biocon Biologics
  38. 4.7.1 Biocon Biologics Company Information
  39. 4.7.2 Biocon Biologics Business Overview
  40. 4.7.3 Biocon Biologics Single-target Anti-VEGF Drugs Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Biocon Biologics Single-target Anti-VEGF Drugs Product Portfolio
  42. 4.7.5 Biocon Biologics Recent Developments
5 Global Single-target Anti-VEGF Drugs Market Scenario by Region
  1. 5.1 Global Single-target Anti-VEGF Drugs Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Single-target Anti-VEGF Drugs Sales by Region: 2021-2032
  3. 5.2.1 Global Single-target Anti-VEGF Drugs Sales by Region: 2021-2026
  4. 5.2.2 Global Single-target Anti-VEGF Drugs Sales by Region: 2027-2032
  5. 5.3 Global Single-target Anti-VEGF Drugs Revenue by Region: 2021-2032
  6. 5.3.1 Global Single-target Anti-VEGF Drugs Revenue by Region: 2021-2026
  7. 5.3.2 Global Single-target Anti-VEGF Drugs Revenue by Region: 2027-2032
  8. 5.4 North America Single-target Anti-VEGF Drugs Market Facts & Figures by Country
  9. 5.4.1 North America Single-target Anti-VEGF Drugs Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Single-target Anti-VEGF Drugs Sales by Country (2021-2032)
  11. 5.4.3 North America Single-target Anti-VEGF Drugs Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Single-target Anti-VEGF Drugs Market Facts & Figures by Country
  16. 5.5.1 Europe Single-target Anti-VEGF Drugs Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Single-target Anti-VEGF Drugs Sales by Country (2021-2032)
  18. 5.5.3 Europe Single-target Anti-VEGF Drugs Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Single-target Anti-VEGF Drugs Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Single-target Anti-VEGF Drugs Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Single-target Anti-VEGF Drugs Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Single-target Anti-VEGF Drugs Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Single-target Anti-VEGF Drugs Market Facts & Figures by Country
  41. 5.7.1 South America Single-target Anti-VEGF Drugs Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Single-target Anti-VEGF Drugs Sales by Country (2021-2032)
  43. 5.7.3 South America Single-target Anti-VEGF Drugs Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa Single-target Anti-VEGF Drugs Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa Single-target Anti-VEGF Drugs Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa Single-target Anti-VEGF Drugs Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa Single-target Anti-VEGF Drugs Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Single-target Anti-VEGF Drugs Sales by Type (2021-2032)
  2. 6.1.1 Global Single-target Anti-VEGF Drugs Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global Single-target Anti-VEGF Drugs Sales Market Share by Type (2021-2032)
  4. 6.2 Global Single-target Anti-VEGF Drugs Revenue by Type (2021-2032)
  5. 6.2.1 Global Single-target Anti-VEGF Drugs Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Single-target Anti-VEGF Drugs Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Single-target Anti-VEGF Drugs Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Single-target Anti-VEGF Drugs Sales by Application (2021-2032)
  2. 7.1.1 Global Single-target Anti-VEGF Drugs Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global Single-target Anti-VEGF Drugs Sales Market Share by Application (2021-2032)
  4. 7.2 Global Single-target Anti-VEGF Drugs Revenue by Application (2021-2032)
  5. 7.2.1 Global Single-target Anti-VEGF Drugs Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Single-target Anti-VEGF Drugs Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Single-target Anti-VEGF Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Single-target Anti-VEGF Drugs Value Chain Analysis
  2. 8.1.1 Single-target Anti-VEGF Drugs Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Single-target Anti-VEGF Drugs Production Mode & Process
  5. 8.2 Single-target Anti-VEGF Drugs Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Single-target Anti-VEGF Drugs Distributors
  8. 8.2.3 Single-target Anti-VEGF Drugs Customers
9 Global Single-target Anti-VEGF Drugs Analyzing Market Dynamics
  1. 9.1 Single-target Anti-VEGF Drugs Industry Trends
  2. 9.2 Single-target Anti-VEGF Drugs Industry Drivers
  3. 9.3 Single-target Anti-VEGF Drugs Industry Opportunities and Challenges
  4. 9.4 Single-target Anti-VEGF Drugs Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst